Pfiz­er makes moves to ac­quire Seagen in po­ten­tial $30B+ deal

Pfiz­er is in talks to ac­quire can­cer drug­mak­er Seagen in a deal that could be worth more than $30 bil­lion, af­ter ac­qui­si­tion talks be­tween Mer­ck and the biotech broke down last year, the Wall Street Jour­nal re­port­ed Sun­day night.

A po­ten­tial deal be­tween Pfiz­er and Seagen isn’t a guar­an­tee and the talks are still at an ear­ly stage, the WSJ re­port­ed, cit­ing peo­ple fa­mil­iar with the mat­ter. Rep­re­sen­ta­tives for Seagen and Pfiz­er de­clined to com­ment.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters